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Chronic renal failure: A cardiovascular risk factor. The risk of
developing cardiovascular disease is greatly increased in pa-
tients undergoing renal replacement therapy and, notably, mor-
bidity and mortality due to therapy is much higher in these
patients than in the general population. Minimal alterations in
renal function, as evidenced by reduced glomerular filtration
rate and the presence of albuminuria, have been described as
potent cardiovascular risk factors.
The classic risk factors only partly explain this difference;
hence, we must admit the existence of known and emerging
factors associated with increased cardiovascular risk in patients
with renal disease. This article provides a review of these fac-
tors. It describes the role of hyperphosphoremia and elevated
calcium-phosphorous product in the formation of cardiovascu-
lar calcifications, the contribution of anemia to left ventricular
hypertrophy, and the consequences of accelerated atheroge-
nesis with oxidative stress and a microinflammatory state re-
sulting from endothelial dysfunction. Hyperhomocysteinemia,
increased sympathetic nervous system activity, lipoprotein alter-
ations with elevated lipoprotein A, and increases in the concen-
trations of asymmetrical dimethyl-arginine are other examples
of the changes described in this population.
Patients with renal disease should be considered to be at high
risk for developing cardiovascular disease and candidates for
implementation of secondary prevention strategies. It is for this
reason that early identification of renal failure, which remains
hidden in many cases, is of prime importance.
EPIDEMIOLOGIC STUDIES PROVIDING
EVIDENCE THAT CHRONIC RENAL DISEASE IS
A CARDIOVASCULAR RISK FACTOR
Chronic renal disease (CRD) has become a consid-
erable health care problem. According to the National
Health and Nutrition Examination Survey III study [1],
CRD affects 8.3 million individuals over 20 years of age
in the United States, that is, 4.6% of the total population.
CRD is a major risk factor for developing end-stage re-
nal disease and cardiovascular disease, and for premature
mortality.
Since the 1970s, it has been known that patients with ad-
vanced CRD undergoing dialysis die from cardiovascular
causes at a younger age than the normal population [2–4].
In the majority of registries of patients undergoing renal
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replacement therapy (United States, Europe, and Japan),
approximately 50% of the deaths have a cardiovascular
cause [5]. The dialysis population in the United States has
a 10- to 20-fold higher risk of death due to cardiovascular
complications than the general population after adjusting
for age, race, and sex, and the relative risk with respect
to the general population is much higher in younger pa-
tients [5]. The risk of cardiac mortality in patients under
45 years of age is 100 times higher than the general pop-
ulation, with differences decreasing with advancing age
[6].
Studies on cardiovascular pathology at the start of dial-
ysis have demonstrated that only 16% of the patients
present with a normal electrocardiogram. The majority
show lesions ranging from left ventricular hypertrophy,
the most common finding, to systolic dysfunction and left
ventricular dilation [7]. In addition, minimum alterations
in renal function, as reflected by changes in glomerular
filtration (GF) or the presence of microalbuminuria, are
related with increased cardiovascular risk [8, 9]. An in-
dependent relationship has been found between reduced
GF and the risk of death, cardiovascular events, and the
need for hospitalization [10]. One population study com-
paring actuarial survival curves adjusted by terciles of
GF found that renal failure is associated with increased
cardiovascular mortality [11].
The Atherosclerosis Risk in Communities Study as-
sessed morbidity and mortality due to stroke/cerebrovas-
cular accident as related to the presence of renal failure.
Patients with renal disease have a high risk of stroke,
regardless of other predictive factors of cerebrovascular
disease, with particularly marked risk in patients with re-
nal disease and anemia [12]. The majority of clinical trials
on pharmacologic treatment for hypertension have ana-
lyzed the relationship between decreased renal function
and cardiovascular morbidity and death as well as any-
cause death, as in the Multiple Risk Factor Intervention
Trial [13]. In the Hypertension Optimal Treatment study,
designed to assess the effect of blood pressure control
on morbidity and mortality, the presence of renal failure
was associated with an elevated relative risk of vascular
events [14].
Because serum creatinine levels and the GF rate do not
correlate linearly, the most reliable method for estimating
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Table 1. Emerging factors and uremia related factors of
cardiovascular risk in CRF
Anemia
Alterations in Ca—P metabolism
Vascular access (increased cardiac output)
Chronic volume expansion
Hyperhomocysteinemia
Dyslipidemia, increased lipoprotein A
Hyperfibrinogenemia, Factor VII
Oxidative stress
Altered nitric oxide/endothelial balance
Inflammation
Malnutrition
Endothelial dysfunction
Ca, calcium; P, phosphorus.
filtration is the use of predictive equations such as the
Cockcroft-Gault and Modification of Diet in Renal Dis-
ease, which take into account the age, sex, and body mass
index of the patient [15].
Several consensus documents, such as the Kidney Dis-
ease Outcomes Quality Initiative guidelines from the
National Kidney Foundation and the American Heart
Association, have underlined the relationship between
CRD and cardiovascular risk. In addition, the most re-
cent guidelines on the management and treatment of
patients with hypertension have included early manifes-
tations of renal insufficiency among the cardiovascular
risk factors. In fact, the Report from the Seventh Joint
National Committee on the Prevention, Detection, Eval-
uation and Treatment of High Blood Pressure, published
in 2003, includes microalbuminuria and a GF rate of <60
mL/min as two cardiovascular risk factors to take into ac-
count and as target organ diseases in hypertension. [16].
UREMIA-RELATED FACTORS THAT
CONTRIBUTE TO CARDIOVASCULAR RISK
In addition to the classic cardiovascular risk factors
such as age, family history of cardiovascular disease,
hypertension, diabetes, dyslipidemia, smoking, and a
sedentary lifestyle, in patients with CRD there several
uremia-related factors and emerging factors to be taken
into account, as shown in Table 1.
The heart and left ventricular hypertrophy
Left ventricular hypertrophy, the most frequent cardiac
alteration in CRD patients, develops early and occurs at
a rate that is inverse to the level of renal function [17].
The factors leading to this alteration are pressure over-
load and volume overload. Pressure overload is induced
by hypertension and results in concentric left ventricu-
lar hypertrophy. Volume overload, which is produced by
chronic hypervolemia, anemia, or hyperdynamic circu-
lation, is associated with increased cardiac output and
favors the development of eccentric left ventricular hy-
pertrophy. Other factors implicated in the development
Table 2. Cardiovascular symptoms related to anemia in CRF
Increased cardiac output
Left ventricular hypertrophy
Palpitations and tachycardia
Angina
Congestive heart disease
Myocardial contractility alterations
of this alteration, including anemia, secondary hyper-
parathroidism, hyperactivity of the sympathetic system,
inflammation, and hyperhomocysteinemia, will be dis-
cussed later. Left ventricular hypertrophy begins as an
adaptive mechanism to accommodate pressure or vol-
ume overload, but later it becomes a maladaptive phe-
nomenon leading to diastolic dysfunction [18].
Anemia as a cardiovascular risk factor
There is a known association between normocytic,
normochromic anemia, and CRD that becomes more im-
portant as GF deteriorates [19]. Anemia appears when
creatinine clearance is less than or equal to 30 mL/min to
40 mL/min (stages 3 and 4 of CRD), and is more severe
in the advanced phases (stage 5 CRD, when the patient
is about to start dialysis treatment). In certain diseases,
such as diabetes, anemia can appear earlier, and in pa-
tients with polycystic renal disease, it may never develop
[20].
Anemia is generally well tolerated, because the organ-
ism has several compensating mechanisms to maintain
tissue oxygenation. However, if it is left unchecked, it will
eventually have severe consequences on several organs
and systems.
Among the physiologic alterations associated with ane-
mia in CRD patients, perhaps the most important are
increased cardiac output, cardiomegaly, left ventricular
hypertrophy, and congestive heart failure [21]. The car-
diovascular symptoms are shown in Table 2. Other alter-
ations such as paleness, intolerance to cold, tiredness, and
muscle weakness are attributable to the relative hypoper-
fusion of the skin and muscle tissue due to redistribution
of the circulating volume toward more vital processes.
Numerous studies have demonstrated a close relation-
ship between cardiovascular morbidity and mortality and
anemia, as well as a relationship between left ventricular
hypertrophy and anemia. [22]. In fact, anemia is consid-
ered one of the uremia-related factors associated with
cardiovascular risk in patients with CRD. According to
data from the Study of Left Ventricular Dysfunction, de-
creased GF and reduced hematocrit have a synergistic
impact on mortality [23]. Data from Medicare consider
anemia a multiplicative risk factor for mortality in pa-
tients with CRD [24]. The hospitalization rate also shows
a relationship with the patient’s degree of anemia [25].
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The availability of erythropoietic stimulating agents
in 1986 brought about notable changes in the treatment
of anemia. First applied only in dialysis patients, in the
decade of the 1990s, erythropoietin use was extended
to correct anemia in CRD. Various studies [22, 26] have
demonstrated partial regression of left ventricular hyper-
trophy after administration of erythropoietin for anemia.
Correction of anemia in CRD improves survival [27], de-
creases morbidity and mortality [28], and increases the
patient’s quality of life [29]. Partial correction of anemia
in patients with heart failure and CRD improves heart
function [30].
Hence, it can be concluded that anemia plays an essen-
tial role in the development of left ventricular hypertro-
phy and mortality in CRD, and that correction of anemia
improves cardiovascular status. Although there is little
information regarding the correction of anemia in CRD,
preliminary, still unpublished results from the Morbi-
Mortality in Chronic Renal Disease study carried out
in Spain by the Study Group for Diabetic Nephropathy
(Grupo Espan˜ol de Estudio de la Nefropatı´a Diabe´tica)
have shown that 46% of patients with stages 4 and 5 of
CRD have anemia with a notable grade of ferropenia.
Nevertheless, nephrologists are increasingly more aware
of the need for early correction of anemia in their pa-
tients, in accordance with the recommendations of the
American Dialysis Outcomes Quality Initiative and re-
cently revised European Best Practice Guidelines [31].
Influence of calcium-phosphorus metabolism on valvular
and vascular calcifications
Vascular calcifications constitute another frequently
occurring cardiovascular risk factor that contributes con-
siderably to the high morbidity and mortality in patients
with CRD. Articles implicating hyperphosphatemia as an
independent risk factor for mortality are becoming in-
creasingly more frequent in the literature [32, 33].
In CRD, vascular calcifications are a consequence of
alterations in mineral metabolism [34]. However, vari-
ous therapeutic measures commonly used for the man-
agement of bone mineral alterations, including elevated
doses of oral calcium in phosphorus chelates together
with vitamin D metabolites, can contribute to the increase
in size of vascular calcifications. Even in the absence of
hypercalcemia, a positive total calcium balance, which is
a cause of calcifications, cannot be ruled out [35]. There
are 2 types of calcifications with different implications. In-
timal calcifications develop in 80% to 90% of atheroscle-
rotic plaques that protrude into the vessel lumen, causing
ischemia and necrosis. Calcification of the media (Mon-
ckeberg sclerosis) occurs diffusely in the tunica media
and is common in CRD and diabetic patients. Calcifi-
cation of the media increases vascular rigidity and de-
creases compliance. This results in systolic hypertension
and increased pulse wave velocity, which contribute to
left ventricular hypertrophy and compromised diastolic
coronary flow. Arterial rigidity due to calcification of the
media is associated with increased mortality. In CRD pa-
tients, the relative absence of protective factors seems to
be linked with the development of vascular calcifications.
A deficit of the glycoprotein, fetuin, a potent inhibitor of
calcification, has been found in these patients [36].
Evidence of vascular calcifications should prompt clin-
icians to review the treatment regimens for osteodys-
trophy, identify the factors that can exacerbate vascular
calcification, and implement measures designed to cor-
rect cardiovascular risk factors—hypertension, dyslipi-
demia, hyperphosphatemia, and excess calcium supply—
to avoid severe complications, such as calciphylaxis [37].
Increased sympathetic nervous system activity: A delete-
rious effect of CRD on the cardiovascular system
Another highly relevant cardiovascular risk factor is
increased activity of the sympathetic nervous system.
Sympathetic hyperactivity has an important role in
CRD-associated hypertension. Renal ischemia, elevated
angiotensin II, and suppression of cerebral nitric oxide
contribute to stimulate sympathetic activity. Accumulat-
ing evidence points to a role of this sympathetic hyperac-
tivity in renal and cardiac injury in patients with CRD
[38, 39]. It seems that decreased availability of nitric
oxide and increased oxidative stress can sensitize target
organs to the deleterious actions of sympathetic hyper-
activity. Moreover, the sympathetic system is not only a
key regulator of cardiovascular function; it also exercises
an important function in the mechanisms controlling the
immune and inflammatory response [40].
Oxidative stress and the microinflammatory state caused
by uremia
Patients with CRD present accelerated atherogenesis
and, as a cause or consequence, show oxidative stress
and an evident microinflammatory state resulting from
endothelial dysfunction, which is present even in the ini-
tial phases of CRD. C-reactive protein is a potent marker
of atherosclerotic complications, and it is a notable pre-
dictor of mortality and cardiovascular events in CRD pa-
tients [41]. The causes of the inflammatory state in these
can be attributed to reduced clearance of proinflamma-
tory cytokines, the uremic state, oxidative stress, and the
presence of associated comorbid conditions such as heart
failure, diabetes, inflammatory diseases, and so forth. In
hemodialysis patients, repeated exposure to bioincom-
patible dialysis membranes, the poor bacteriologic qual-
ity of the dialysis fluid, and the presence of foreign bodies
such as polytetrafluoroethylene prostheses and catheters,
together with evident or asymptomatic infection, all con-
tribute to increasing the inflammatory state.
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Perticone [42] has suggested that alterations in the va-
sodilator response to acetylcholine are associated with
a loss of renal function in patients with essential hyper-
tension. This association suggests that endothelial dys-
function would play a slight to moderate role in renal
failure in patients with uncomplicated hypertension. Sev-
eral in vitro studies have demonstrated that modified low-
density lipoprotein, advanced glycosylation end products,
cytokines, homocysteine, and lipoprotein A are respon-
sible for the production of oxygen free radicals, a cause
of oxidative stress [43, 44].
Fibrinogen is an acute phase reactant whose levels cor-
relate with inflammation markers in patients with CRD.
Although fibrinogen levels are increased in CRD patients
under dialysis [45], the results in the literature are con-
troversial regarding its role as a predictor of all-cause and
cardiovascular mortality. This may be because fibrinogen,
which is closely linked to other cardiovascular risk mark-
ers and to inflammation, loses significance when these
factors are included in the predictive model.
Homocysteine and CRD: A still uncertain relationship
Homocysteine is moderately elevated in the initial
phases of CRD and increases as GF deteriorates. Data
in the literature on the relationship between homocys-
teine and cardiovascular events are not conclusive, prob-
ably because of the coexistence of confounding factors,
attributable to inflammation and malnutrition [46].
Other abnormalities with relevant pathogenic poten-
tial must be attributed to alterations in the lipoprotein
pattern, with elevated lipoprotein A [47], as well as in-
creased concentrations of oxide-nitric synthetase, and
asymmetrical dimethyL-arginine [48].
The metabolic syndrome and its relationship with CRD
The metabolic syndrome, characterized by abdomi-
nal fat accumulation hypertension, hypertriglyceridemia,
low high-density lipoprotein levels, and hyperglycemia
[49], has been associated with an increased risk of de-
veloping diabetes mellitus and cardiovascular disease, as
well as a higher risk of death by cardiovascular and other
causes. Nevertheless, there is little data in the literature
on the relationship between the metabolic syndrome and
CRD. Some recent studies [50, 51], however, have sug-
gested that the risk of developing CRD and microalbu-
minuria progressively increases parallel to the number
of components of metabolic syndrome, regardless of age,
sex, race, and the presence of other potential risk factors
for CRD.
CONCLUSION
Elevated urinary excretion of albumin or proteins is
a risk factor for cardiovascular disease both in diabetic
and nondiabetic patients. Poor creatinine clearance and
low GF are also risk factors in patients with and with-
out diabetes. Patients with CRD, defined as those with
persistent renal injury, such as microalbuminuria or pro-
teinuria, or a GF rate <60 mL/min/1.73 m2, regardless of
the cause, have a higher risk of developing cardiovascular
disease, including coronary disease, cerebrovascular dis-
ease, peripheral artery disease, and heart failure. Hence,
they should be considered patients at high cardiovascular
risk requiring secondary prevention strategies.
All these pathogenic mechanisms are priority areas of
interest for future investigation, considering the epidemi-
ologic demonstration of a progressive increase in CRD,
mainly because of increasing detection of occult renal
failure. The scientific community of nephrologists and the
Spanish Society of Nephrology in our country have ini-
tiated studies to determine the prevalence of CRD in
the general population. It is essential to make nephrolo-
gists and general practitioners aware of the importance
of early detection and secondary prevention in patients
with CRD to offset the high cardiovascular risk associ-
ated with this disease.
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